Authors
Loading...
Review highlights the utility of surrogate endpoints alongside overall survival in oncology trials, suggesting novel markers accelerate cancer drug approvals.
Patil et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: